Hyperparathyroidism Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Hyperparathyroidism Treatment Market is segmented By Product (Parathyroid Hormone, Vitamin D Analogue, Calcium Supplements), By Route of Administration (Oral, Intravenous, Subcutaneous), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned.
Hyperparathyroidism Treatment Market Size
Market Size in USD
CAGR6.9%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 6.9% |
| Market Concentration | Medium |
| Major Players | Pathalys Pharma, Amgen Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Roche Holding AG |
please let us know !
Hyperparathyroidism Treatment Market Analysis
The Global Hyperparathyroidism Treatment Market is estimated to be valued at USD 780.1 Mn in 2024 and is expected to reach USD 991.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
The hyperparathyroidism treatment market is expected to witness positive growth over the forecast period due to the rising prevalence of hyperparathyroid disorders and increasing adoption of minimally invasive surgeries. According to a recent survey, hyperparathyroidism affects around 1 in 1000 adults annually in the United States. With growing geriatric population, the cases of primary hyperparathyroidism are increasing at a faster pace thus driving the demand for treatment solutions. Moreover, technological advancements in medical imaging techniques have enabled precise localization of abnormal parathyroid glands thereby enabling minimally invasive surgeries such as minimally invasive parathyroidectomy (MIP). MIP procedures require smaller incision resulting in lower healthcare costs, less surgical complications, and faster recovery time. This trend towards less invasive surgeries is favoring the growth of hyperparathyroidism treatment market during the forecast period.